Pulmonx Corp (NASDAQ: LUNG) — Perfil da empresa, notícias e dados financeiros
Pulmonx specializes in medical technologies for lung diseases, known for the minimally invasive Zephyr Valve.
Pulmonx Corp
Pulmonx (NASDAQ:LUNG) specializes in innovative medical technologies and solutions focused on improving the lives of people suffering from lung diseases, specifically those with severe emphysema. The company is renowned for its development, manufacture, and sale of minimally invasive medical devices aimed at enhancing pulmonary function and reducing the symptoms of lung conditions. Pulmonx's flagship product, the Zephyr Valve, is a revolutionary device that offers a nonsurgical treatment option for patients with emphysema, demonstrating the company's commitment to advancing respiratory health through innovation. With a strong emphasis on research and development, Pulmonx aims to continually expand its product portfolio, ensuring it meets the evolving needs of patients and healthcare professionals around the world.
Resumo
Operações
Produtos e/ou serviços de Pulmonx Corp
- Offers the Zephyr Endobronchial Valve: An implantable device that reduces lung hyperinflation in severe emphysema patients.
- Provides the StratX Lung Analysis Platform: A cloud-based software tool used to assess patients for suitability for the Zephyr Valve.
- Develops the Chartis Pulmonary Assessment System: A device for measuring lung function and collateral ventilation.
- Conducts clinical trials: They actively research and develop new treatments for COPD and other lung diseases.
- Offers physician training and education: They provide resources and support to healthcare professionals treating COPD patients.
- Engages in reimbursement activities: They work with healthcare payers to secure coverage for their products and services.
equipe executiva do Pulmonx Corp
- Glendon E. FrenchCEO, President & Director
- Derrick SungCFO & COO
- David A. LehmanGeneral Counsel & Secretary
- Srikanth RadhakrishnanChief Science & Technology Officer
- Marcee M. MaroneyVice President of Marketing
- Jérôme ErathSenior VP & GM of International
- Geoffrey Beran RoseChief Commercial Officer
- Narinder S. ShargillSenior Vice President of Global Medical & Clinical Affairs
- John B. McKuneVP of Finance & Corporate Controller
Principais indicadores financeiros
Resultados divulgados pela Pulmonx Corp, em USD.
- Cap. de mercado
- 85 mi
- Receita (TTM)
- 87,4 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.1
- Dividend yield
- —
- Margem de lucro
- -55.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 90,5 mi | -53,7 mi | -54 mi | |
| 83,8 mi | -57,7 mi | -56,4 mi | |
| 68,7 mi | -61,9 mi | -60,8 mi | |
| 53,7 mi | -58,6 mi | -58,9 mi |